

EDRN Steering Committee Meeting
Wednesday, February 21, 2024, 3:30 pm ET

Present:

- Arizona State University: N/A
- NCI: Sudhir Srivastava, Felicia Evans-Long, Sidney Fu, Nick Hodges, Indu Kohaar, Amit Kumar, Guillermo Marquez, Richard Mazurchuk, Mark Miller, Christos Patriotis, Neeraj Saxena, Amanda Skarlupka, Paul Wagner, Wendy Wang, Matt Young, Kelly Crotty (Guest)
- Baylor: Fasiha Kanwal, Erich Sturgis
- Boston University: Marc Lenburg, Jennifer Beane, Erin Kane
- Dana-Farber Cancer Institute: Sapna Syngal
- Fred Hutchinson Cancer Center: Jackie Dahlgren, Amanda Paulovich, Cecilia Yeung
- Icahn School of Medicine Mt. Sinai: Pei Wang
- JPL: Daniel Crichton, Heather Kincaid
- Johns Hopkins University: Daniel Chan le-Ming Shih, David Sidransky, Hui Zhang, Zhen Zhang
- Massachusetts: Steven Skates, Alan Cha
- Meso Scale: Anu Mathew, Martin Stengelin, Mingyue Wang
- NIST: Hua-Jun He
- New York University: Harvey Pass, Leopoldo Segal
- PNNL: Tao Liu
- University of California, Los Angeles: William Hsu, Mike Palazzolo
- University Health Network: Thomas Kislinger
- University of Pittsburgh: Randall Brand, James Herman
- University of Maryland: Sanford Stass
- University of Michigan: Neehar Parikh
- University of North Carolina: Nicholas Shaheen
- University of Texas MD Anderson: Robert Bast, Robert Bresalier, Anirban Maitra, Ed Ostrin, David Wilson
- University of Texas Southwestern: Amit Singal
- University of Washington: William Grady, Savannah Partridge
- Vanderbilt: Stephen Deppen, Michael Kammer, Jeff Tosoian

Action Items from this Meeting:

1. Ongoing: DMCC post the presentations to the secure Steering Committee section for this meeting on the EDRN Portal.
2. Ongoing: DMCC to post slides about funding opportunities.
3. Ongoing: Committee members to volunteer to present at upcoming steering committee meetings.

Welcome:

Dr. Arul M. Chinnaiyan opened the meeting and announced that Drs. Joshua LaBaer and Karen Anderson are absent.

Updates:

- NCI Updates
 - Dr. Sudhir Srivastava said that Dr. Ratman is joining NCI.
 - Planning of meeting in Tempe is almost done and schedule is available on public portal. Dr. Sudhir Srivastava encouraged everyone to attend, and if unable to attend, send someone from your group. Travel funds for EDRN are not able to be transferred to another category.
 - Continuing Resolution is being extended, until NCI gets the full budget, they won't have a clear idea about reductions.

- Steering Committee Updates (CUT, Set Asides, DMCC)
 - CUT:
 - Dr. Fasiha Kanwal said that the utility trial has been launched. They have started enrollment at five sites and the randomization is working well. Patients are okay with being randomized and uptake is going well in terms of sites, providers, physicians, clinicians. Still working through issues with the database. Additional sites are currently being added, including UCSF and Indiana.
 - Lung: Dr. Eric Grogan said they are running samples and getting completed scans for the LTP2, to do both blood- and imaging-based biomarkers, which is a different biomarker strategy. They are in the process of redesigning their R01 so they can run a pragmatic radiomic biomarker clinical utility trial which is being pushed through their IRB. They had some setbacks with their instruments for biomarkers.
 - Dr. Jeff Tosoian said they are meeting with the group this week to discuss next steps and prepare resubmission.
 - DMCC:
 - Dr. Ziding Feng said Dr. Yingye Zheng is traveling, and he will give the updates. Their main emphasis is on supporting the Clinical Utility Trial. They are using the metadata RAVE data system, which has been a learning curve.
- Associate Membership Program
 - Next deadline is March 1.

NCI Programs:

- Dr. Altaf Mohammed, NCI, gave presentation on the following programs:
 - [RFA-CA-23-029 Overview of Cancer Immunoprevention Network \(CIP-Net\)](#).
 - Highlights: Utilizes the UG3/UH3 cooperative agreement mechanism managed by NCI staff, and a U24 Resource Coordinating center. Start as UG3, then upon completion of milestones, pass into UH3 phase. Direct costs are \$500K/year, program is five years (two years UG3 phase, three years UH3 phase), 10-12 awards to be funded across FY24 and FY25. Due Date is July 3, 2024.
 - Scientific Objectives include: Supporting a deeper understanding of basic mechanisms of immunoprevention, discovering novel immunoprevention strategies, and fostering a community of cancer immunoprevention researchers. Builds on IOTN's progress toward the Cancer Moonshot Immunology Working group goal to prevent cancers before they occur. Leveraging the success of mRNA vaccines to address cancer immunoprevention strategies. Contributes to building the Cancer Immunoprevention Research Continuum.
 - [RFA-CA-23-029 Discovery and Development of Natural Products for Cancer Interception and Prevention](#)
 - Highlights: Utilizes the UG3/UH3 cooperative agreement mechanism. Direct costs are \$250K/year for UG3 phase and \$400K/year for UH3 phase. Program is five years (~three years UG3 phase, two years UH3 phase). ~12 awards total across years FY24, FY25, and FY26.
 - Scientific Objectives include: Establish a Cancer Immunoprevention Network (CIP-Net) to support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, preclinical development and testing of interventions, and foster a community of cancer immunoprevention researchers.
 - Restricted to natural products only.
 - DMCC to post slides from this presentation to public portal

Scientific Presentation:

- ACTION: Dr. Arul Chinnaiyan asked the Committee for volunteers for Future steering committee meetings looking for EDNRN related publications to present by contacting Dr. Guillermo Marquez and Jackie Dahlgren. Dr. Sudhir Srivastava said they will highlight publications on EDNRN website.
- Dr. Jeffrey Tosoian, M.D., Ph.D., presented on upcoming publication in JAMA Oncology "Development and Validation of a Novel 18-Gene Urine Test for Clinically Significant Prostate Cancer."
 - Slides are available on the EDNRN Portal in the secure Steering Committee section for this meeting.

Committee Updates (5-10 min each)

1. Reference Set Committee
 1. Dr. Bob Bresalier said they are having monthly meetings, and the algorithm is working. They were able to get input from the appropriate group for feedback. There was a request from a commercial venture outside of the country, their request was vague. Dr. Bob Bresalier's group requested more data and suggested collaboration with EDRN.
2. Statistical Group Update
 1. Dr. Ziding Feng said Dr. Yingye Zheng is the new chair. The group is very active right now, with a focus on the clinical utility trial. There is a discussion to have a meeting to address these issues.
3. Early-Stage Investigators Forum
 1. Dr. Matt Young said their meeting was not well attended, with two speakers, a chairperson, and mostly people from NCI. He said they need more EDRN participants at this meeting, as the representatives from each group did not attend. They recommend discussing who is eligible to attend the early-stage investigator meetings.

Closing:

Next Call: Wednesday, April 17, 2024, at 12:20 pm MST in Tempe Arizona